Trial Profile
Overall survival (OS) and tolerance to sorafenib in a real life large cohort of Child-Pugh B with advanced hepatocellular carcinoma (HCC) compared toChild-Pugh A with hepatocellular carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2018 New trial record
- 13 Jun 2018 Results published in the Investigational New Drugs.